Global Invasive Fungal Infections Market Report 2023: Increasing Invasive Fungal Infections with Life-threatening Conditions Drive Growth - ResearchAndMarkets.com
Retrieved on:
Monday, May 29, 2023
Biotechnology, Pharmaceutical, Health, Molecule, Amphotericin B, Fungal infection, Risk factor, Imidazole, Prevalence, Diabetes, HIV, Blastomycosis, Posaconazole, Infection, Candidiasis, Overalls, Isavuconazonium, Ageing, Mucormycosis, Merck & Co., Polyene, Fungemia, CDC, Incidence, AR, Patient, Developed country, ROW, Growth, Mortality, Merck, Immunodeficiency, Immunosuppression, Cryptococcus, Pfizer, Triazole, Pharmaceutical industry, Vaccine, Voriconazole, Echinocandin, Aspergillosis, Azole, Fluconazole
However, there are also antibody molecules in early preclinical development, which are currently not on the market.
Key Points:
- However, there are also antibody molecules in early preclinical development, which are currently not on the market.
- The increasing use of broad-spectrum antibiotics, the aging population, and the growing prevalence of immunocompromised patients are driving the growth of invasive candidiasis.
- By Region: The report provides insight into the invasive fungal infections market based on the geographical operations, namely North America, Europe, Asia Pacific, and ROW.
- The North American region has emerged as a dominant player in the invasive fungal infections market, owing to several key factors.